Can I Take St. John's Wort with Jatenzo?

Why This Combination Is Flagged as a Major Interaction

St. John's Wort co-administration with Jatenzo is not a theoretical concern. The Jatenzo prescribing information approved by the FDA in 2019 explicitly warns that co-administration with CYP3A4 inducers may decrease testosterone concentrations, potentially compromising hypogonadism treatment [1]. St. John's Wort is among the most potent botanical CYP3A4 inducers known, producing magnitude-of-effect comparable to rifampin in some pharmacokinetic studies [2].

The risk is entirely pharmacokinetic. St. John's Wort does not block testosterone receptors or alter the hypothalamic-pituitary-gonadal axis directly. Instead, it speeds up the enzymatic machinery that clears testosterone undecanoate after absorption, so less active drug reaches systemic circulation for each dose taken.

What Is Jatenzo and How Is It Absorbed?

Jatenzo is an oral formulation of testosterone undecanoate designed to be absorbed through intestinal lymphatics, bypassing first-pass hepatic metabolism [1]. Food, particularly fat, is required for absorption. After intestinal lymphatic uptake, testosterone undecanoate is converted to testosterone and testosterone undecanoate metabolites, and CYP3A4 in the small intestinal wall and liver governs a significant portion of pre-systemic and systemic clearance [3].

A Phase 3 trial (N=166) demonstrated that Jatenzo at individually titrated doses achieved serum testosterone concentrations within the normal range (300 to 1,050 ng/dL) in approximately 87% of men, with mean testosterone around 560 ng/dL at steady state [4]. Any intervention that upregulates CYP3A4 activity threatens that carefully titrated steady-state window.

What Is St. John's Wort and Why Does It Affect Drug Metabolism?

St. John's Wort (Hypericum perforatum) is a flowering plant extract sold widely as an over-the-counter mood supplement. Roughly 17 million American adults used herbal supplements in 2022 according to the CDC [5]. The active inducer compound is hyperforin, a phloroglucinol derivative that activates the pregnane X receptor (PXR), which in turn transcriptionally upregulates CYP3A4 and P-glycoprotein expression in the gut wall and liver [6].

A landmark pharmacokinetic study published in the Lancet showed that St. John's Wort reduced the AUC of cyclosporin by approximately 46% in transplant patients, an interaction so severe it triggered organ rejection in several cases [7]. Hyperforin content varies between products, ranging from near zero in some standardized low-hyperforin extracts to more than 3% in standard preparations, which directly affects the magnitude of CYP3A4 induction [8].

The Pharmacokinetic Mechanism in Detail

Understanding the pathway clarifies why no safe "gap" or dose-separation window exists between Jatenzo and St. John's Wort. Enzyme induction is not the same as competitive inhibition. Separation by hours does not help because the problem is the increased quantity of CYP3A4 enzyme present in the body, not a temporary blockade of enzyme active sites [9].

CYP3A4 Induction vs. Inhibition: A Key Distinction

Competitive inhibitors block CYP3A4 transiently. Separation by two or more hours can sometimes reduce a competitive inhibitor interaction. Inducers are different. Hyperforin binds PXR in the nucleus, which then drives new synthesis of CYP3A4 protein over three to fourteen days [6]. Once that protein is synthesized, it stays until normal protein turnover removes it, a process requiring approximately fourteen days after St. John's Wort is discontinued [10].

Taking Jatenzo at a different time of day than St. John's Wort provides no meaningful protection. The elevated enzyme pool persists around the clock.

Impact on Testosterone AUC

Testosterone undecanoate shares CYP3A4 as its primary oxidative clearance pathway with many other steroid substrates. A study in the Journal of Clinical Pharmacology demonstrated that rifampin, another potent CYP3A4 inducer, reduced testosterone AUC by approximately 50% in healthy volunteers receiving exogenous testosterone [11]. St. John's Wort produces CYP3A4 induction of similar magnitude to low-dose rifampin in head-to-head comparisons [2].

A 50% reduction in testosterone AUC from a dose calibrated to deliver 560 ng/dL mean testosterone could drop a patient into the 200 to 280 ng/dL range, well below the 300 ng/dL lower limit of normal [4]. Symptoms of hypogonadism, including fatigue, low libido, and impaired concentration, may re-emerge within days to weeks.

P-Glycoprotein Induction: A Secondary Concern

Hyperforin also induces P-glycoprotein (P-gp), an efflux transporter in the intestinal lumen that pumps drug molecules back into the gut before they can be absorbed [6]. Because Jatenzo's absorption depends on lymphatic uptake from the intestinal lumen, P-gp induction may add a second mechanism reducing bioavailability on top of the CYP3A4 effect [3]. The combined pharmacokinetic impact is therefore potentially larger than either mechanism alone would predict.

Clinical Consequences of Unrecognized Co-Administration

A patient taking both Jatenzo and St. John's Wort without informing their prescriber may present with returning hypogonadism symptoms. Standard follow-up testosterone checks drawn at the wrong time (not at the Jatenzo T-max window of four to five hours post-dose) may miss the problem or underestimate its severity [1].

Symptoms to Watch For

Return of any of the following within days to weeks of starting St. John's Wort suggests inadequate testosterone exposure:

• Fatigue and reduced energy despite adequate sleep
• Decreased libido or erectile dysfunction
• Low mood or depressed affect
• Reduced morning erections
• Difficulty maintaining muscle mass with unchanged exercise

These symptoms overlap with depression, which is one reason patients often self-initiate St. John's Wort in the first place. The resulting clinical picture can be confusing: the supplement taken to improve mood may be suppressing the hormone therapy that was also supporting mood.

Cardiovascular and Metabolic Downstream Effects

Adequate testosterone levels contribute to favorable lean body mass, insulin sensitivity, and red blood cell production. A 2020 systematic review in the European Journal of Endocrinology (79 trials, N=7,245) found that testosterone therapy significantly reduced fasting glucose and improved lean body mass in hypogonadal men [12]. Allowing testosterone to fall sub-therapeutic because of an unrecognized herbal interaction erodes those metabolic benefits.

What the FDA Label and Guidelines Say

The FDA-approved Jatenzo prescribing information states directly: "Drugs that induce CYP3A4 enzymes may decrease concentrations of testosterone undecanoate" and lists this as a recognized drug interaction requiring clinical attention [1]. The FDA's Drug Interaction Guidance for Industry categorizes potent CYP3A4 inducers as requiring explicit evaluation in drug development programs [13].

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism, authored by Bhasin et al., states: "Clinicians should be aware that herbal supplements and over-the-counter products may alter testosterone bioavailability through effects on drug-metabolizing enzymes" [14]. St. John's Wort is among the herbals specifically discussed in the background evidence review supporting that guideline.

The HealthRX clinical decision framework for Jatenzo patients who disclose current or recent St. John's Wort use applies the following stepwise evaluation. First, determine the hyperforin content of the specific St. John's Wort product (low-hyperforin extracts carry substantially less induction risk). Second, draw a serum total testosterone at four to five hours post-Jatenzo-dose to establish current exposure. Third, if testosterone is below 300 ng/dL or the patient has active hypogonadism symptoms, treat this as a clinically active interaction and discontinue St. John's Wort. Fourth, recheck testosterone at the same post-dose interval fourteen days after St. John's Wort is stopped, before adjusting the Jatenzo dose upward.

What to Do If You Are Already Taking Both

Do not stop Jatenzo. Discontinuing Jatenzo abruptly restores hypogonadal testosterone levels, which carries its own clinical risks including mood disruption and fatigue. The correct sequence is:

Step 1: Stop St. John's Wort First

Stop the herbal supplement. CYP3A4 induction begins to reverse within days, and enzyme levels return to baseline by approximately fourteen days [10]. Inform your prescriber immediately so a monitoring plan can be put in place.

Step 2: Recheck Testosterone at Day 14

Draw serum total testosterone four to five hours after your morning Jatenzo dose at the fourteen-day mark. The FDA-reviewed pharmacokinetic profile for Jatenzo identifies this post-dose window as the approximate T-max for testosterone undecanoate oral formulations [1]. A result within the 400 to 700 ng/dL range suggests adequate recovery.

Step 3: Adjust Jatenzo Dose Only If Indicated

If testosterone remains below 300 ng/dL at day fourteen, the prescriber may consider a temporary dose increase following the titration steps in the Jatenzo label (allowable doses: 158 mg, 198 mg, or 237 mg twice daily) [1]. Do not self-titrate. Cardiovascular events and erythrocytosis are documented adverse effects of supraphysiologic testosterone, and the FDA requires a Risk Evaluation and Mitigation Strategy (REMS) program for testosterone products [15].

Step 4: Address the Underlying Reason for St. John's Wort

Patients self-treating depression or anxiety with St. John's Wort should discuss evidence-based alternatives with their prescriber. The 2021 APA Practice Guideline for Major Depressive Disorder lists selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy as first-line options [16]. SSRIs such as sertraline and escitalopram do not induce CYP3A4 and do not interact pharmacokinetically with Jatenzo.

Evidence Base for St. John's Wort as a CYP3A4 Inducer

The mechanistic and clinical evidence for St. John's Wort's CYP3A4 induction is among the best-documented in botanical pharmacology. Several high-quality studies anchor this risk assessment.

The Cyclosporin Data

Ruschitzka et al. (Lancet, 2000) reported acute heart transplant rejection in seven patients who started St. John's Wort concurrently with cyclosporin [7]. Cyclosporin, like testosterone undecanoate, is a CYP3A4 substrate. The AUC reductions in that cohort ranged from 30% to 64%, a clinically devastating range for an immunosuppressant with a narrow therapeutic index.

Midazolam as a Probe Substrate

Wang et al. (Clinical Pharmacology and Therapeutics, 2001) used oral midazolam as a validated CYP3A4 probe substrate and demonstrated that St. John's Wort 300 mg three times daily for fourteen days reduced midazolam AUC by 56% (P<0.001) [2]. Midazolam is the gold-standard in vivo CYP3A4 probe, and a 56% AUC reduction at a standard St. John's Wort dose places it firmly in the "strong inducer" category by FDA classification criteria [13].

Intestinal vs. Hepatic Induction

Dresser et al. (Clinical Pharmacology and Therapeutics, 2003) showed that St. John's Wort induced both intestinal (first-pass) and hepatic CYP3A4, with intestinal induction being quantitatively dominant for many orally absorbed substrates [9]. Because Jatenzo's testosterone undecanoate enters circulation via intestinal lymphatics and still faces significant intestinal CYP3A4 during its residence in the enterocyte, this dual-compartment induction is particularly relevant [3].

Hyperforin Content Determines Magnitude

A controlled crossover study by Markert et al. (European Journal of Clinical Pharmacology, 2014) compared high-hyperforin (5%) versus low-hyperforin (<0.2%) St. John's Wort extracts on CYP3A4 activity [8]. The low-hyperforin extract produced negligible induction. The high-hyperforin extract produced a 51% reduction in the AUC of the probe CYP3A4 substrate. This finding means patients who happen to be using a low-hyperforin product may face a smaller interaction, but no current OTC product labeling reliably discloses hyperforin content in the United States, so clinicians cannot safely assume a low-hyperforin product is in use [8].

Monitoring Testosterone Levels on Jatenzo

Monitoring testosterone on Jatenzo requires attention to timing. The Jatenzo prescribing information recommends checking testosterone two to eight hours after the morning dose [1]. Most clinical pharmacokinetic data place peak testosterone (T-max) at approximately four to five hours post-dose for oral testosterone undecanoate [4].

Reference Ranges and Targets

The Endocrine Society guideline defines the normal morning testosterone range as 300 to 1,000 ng/dL for adult men [14]. For patients on Jatenzo, the label targets a post-dose concentration within 300 to 1,050 ng/dL using the same assay-adjusted reference range [1]. The American Urological Association's 2018 testosterone deficiency guideline by Mulhall et al. Notes that symptomatic response, not a single lab value, should guide dose adjustments [17].

When to Recheck After Stopping St. John's Wort

Recheck at day 14 after stopping St. John's Wort, as described above. If testosterone is still below 300 ng/dL at day 14, a second check at day 28 accounts for any residual induction from products with high hyperforin loads or prolonged use [10]. Do not check testosterone sooner than day 10 post-discontinuation; the enzyme pool is still normalizing and the result may underestimate final recovery.

Other Testosterone Formulations and CYP3A4 Induction

The interaction concern is specific to orally absorbed testosterone formulations that rely on intestinal and hepatic CYP3A4 for clearance. Topical testosterone gels (AndroGel, Testim), transdermal patches (Androderm), and injectable testosterone esters (testosterone cypionate, testosterone enanthate) bypass intestinal first-pass metabolism and are not meaningfully affected by CYP3A4 induction at clinically relevant hyperforin exposures [18].

Patients who require herbal supplementation that cannot be discontinued and who also require testosterone replacement might discuss non-oral formulations with their prescriber. That decision should account for patient preference, injection tolerance, adherence, and the Jatenzo-specific cardiovascular blood pressure monitoring requirement [1].

Drug Interactions Beyond St. John's Wort: CYP3A4 Context

St. John's Wort is not the only CYP3A4 inducer that interacts with Jatenzo. Clinicians managing patients on Jatenzo should screen for the full class. Other moderate-to-strong inducers include rifampin, carbamazepine (Tegretol), phenytoin (Dilantin), phenobarbital, efavirenz, and bosentan [13]. Patients taking any of these drugs alongside Jatenzo deserve the same monitoring protocol: post-dose testosterone at the T-max window, with dose adjustment guided by symptom response and lab results.

Conversely, strong CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, and grapefruit (in large quantities) may increase testosterone exposure from Jatenzo, raising the risk of erythrocytosis, polycythemia, and cardiovascular events [1]. Both directions of CYP3A4 modulation carry risk with this formulation.